[1] Piérard-Franchimont C, Deleixhe-Mauhin F, Piérard GE. Dermatophytose cutanée chronique, onychomycose occulte et hamartome épidermoïde linéaire: une impasse thérapeutique. J Mycol Med, 1996,6:190-194.
[2] Elewski BE. Onychomycosis:treatment, quality of life and economic issues. Am J Clin Dermatol, 2000,1:19-26.
[3] Arrese JE, Pirard-Franchimont C, Piérard GE. Facing up to the diagnostic uncertainty and management of onychomycoses. Int J Dermatol, 1999,38(Suppl 2):1-6.
[4] Haneke E. Fungal infections of the nail. Semin Dermatol, 1991,10:41-53.
[5] Piérard GE, Arrese JE, Pierre S, et al. Diagnostic microscopique des onychomycoses. Ann Dermatol Venereol, 1994,121:25-29.
[6] Arrese JE, Piérard-Franchimont C, Greimers R, et al. Fungi in onychomycosis: a study by immunohistochemistry and dual flow cytometry. J Eur Acad Dermatol Venereol, 1995,4:123-130.
[7] Greer DL. Evolving role of nondermatophytes in onychomycosis. Int J Dermatol, 1995,34:521-524.
[8] Ginter G, Rieger E, Heigl K, et al. Increasing frequency of onychomycosis-is there a change in the spectrum of infectious agents. Mycoses, 1996,39(Suppl 1):118-122.
[9] Wang DL. Pathogen investigation on onychomycosis: a multicenter study. Chin J Dermatol, 1996,29:61-62.
[10] Kam KM, Au WF, Wong PY, et al. Onychomycosis in Hong Kong. Int J Dermatol, 1997,36:757-761.
[11] Ellis DH, Marley JE, Watson AB, et al. Significance of non-dermatophyte moulds and yeasts in onychomycosis. Dermatology, 1997,194(Suppl 1):40-42.
[12] Summerbell RC. Epidemiology and ecology of onychomycosis. Dermatology, 1997,194(Suppl 1):32-36.
[13] Piérard GE, Arrese JE, De Doncker P, et al. Present and potential diagnostic techniques in onychomycosis. J Am Acad Dermatol, 1996,34:273-277.
[14] De Doncker P.Pharmacokenetics of orally administered antifungals in onychomycosis. Int J Dermatol, 1999,38(Suppl 2):20-27.
[15] Galgiani JN. Susceptibility testing of fungi: current status of the standardization process. Antimicrob Agents Chemother, 1993,37:2517-2521.
[16] Elewski BE. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol, 1993,28:S28-S34.
[17] Piérard-Franchimont C,Goffin V,Arrese JE, et al. Biometrology applied to cyanoacrylate skin surface strippings: a review of the Liè ge experience. Dermatol Clin, 1999,19:93-97.
[18] Piérard GE, Arrese JE, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol, 1995,32:429-435.
[19] Arrese JE, De Doncker P,Odds F, et al. Reduction in the growth of non-dermatophyte moulds by itraconazole: evaluation by corneofungimetry bioassay. Mycoses, 1998,41:461-465.
[20] De Doncker P, Decroix J, Piérard GE, et al. Antifungal pulse therapy in onychomycosis: a phamacokinetic/pharmacodynamic investigation of monthly cycles of 1 week pulse with itraconazole. Arch Dermatol, 1996,132:34-41.
[21] De Doncker P, Scher RK, Baran RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol, 1997,36:173-177.
[22] Piérard GE, Arrese JE, Theunis A, et al. Onychomycosis revisited and itraconazole pulse therapy: a global perspective. Mik Lekarska, 1998,5:69-73.
[23] Gupta AK, Lambert J. Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA. Int J Dermatol, 1999,38(Suppl 2):53-64.
[24] Piérard GE,Arrese JE,Piérard-Franchimont C. Itraconazole. Expert Opin Pharmacother, 2000,1:287-304.
[25] 陈志强,徐文严,陈祥生,等.伊曲康唑在我国的应用:五年临床经验回顾.中华皮肤科杂志,1999,32:330-334.
[26] Piérard GE,Piérard-Franchimont C,Arrese JE. The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Dermatology, 2000,200:185-187.
[27] Pirard G E,Piérard-Franchimont C,Arrese J E,etal.原发性病原真菌和条件性真菌可致的甲真菌病.中华皮肤科杂志,1998,31:308-309. |
